ArticleInternational journal of surgery (London, England)2026
Long-term conditional relative survival trends in extrahepatic bile duct cancer: insights from a population-based retrospective cohort study in a high-incidence Asian Country, 1999-2021.
Article in International journal of surgery (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Early Recurrence Limits Post-recurrence Therapy in Biliary Tract Cancer: A Rationale for Neoadjuvant Chemotherapy.Annals of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDynamic prognostic information is crucial for treatment decisions and patient consultations in extrahepatic bile duct (EHBD) cancer, given its poor prognosis. This study aimed to investigate the long-term conditional relative survival (CRS) rates among patients with EHBD cancer in Korea, where its incidence is notably high. MATERIALS AND
methodsData from 46 916 individuals diagnosed with EHBD cancer between 1999 and 2021 were obtained from the Korea Central Cancer Registry (KCCR) for this retrospective cohort study. CRS was analyzed according to various strata, including the Surveillance, Epidemiology, and End Results (SEER) stage and the first course of treatment.
resultsThe 5-year survival probability at diagnosis was 20.8%, whereas the conditional probability of surviving to the fifth year for patients who had already survived 1, 2, 3, and 4 years after diagnosis (the probability of surviving an additional 4, 3, 2, and 1 year) was 35.4%, 55.5%, 74.0%, and 88.6%, respectively. Among the 5-year survivors, 72.4% lived for an additional 5 years. For patients who underwent surgery at the localized or regional stage, the 5-year survival rates at diagnosis were 53.5% and 34.7%, respectively. Among 2-year survivors, 71.7% (localized) and 56.6% (regional) survived to the 5 years after diagnosis, and among 5-year survivors, 73.0% (localized) and 69.0% (regional) lived for an additional 5 years.
conclusionThe long-term survival rate among patients with EHBD cancer did not plateau, even among 5-year survivors with localized-stage disease, as it continued to decline over time. These findings suggest that continued surveillance and individualized assessments are warranted for patients with EHBD cancer throughout long-term follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.